GNH USA

Europe — EMA

Mibg (I123) Curium Netherlands (Iodine (123i) Iobenguane)

GNH USA supplies Mibg (I123) Curium Netherlands (Iobenguane I-123), a diagnostic radiopharmaceutical for neuroblastoma, pheochromocytoma and cardiac

Iodine (123i) Iobenguane

Request sourcing

1
Pack/s

What is Iodine (123i) Iobenguane?

Iobenguane I-123, the active ingredient in Mibg (I123) Curium Netherlands, is a diagnostic radiopharmaceutical presented as an injectable solution for intravenous use. It is employed to visualize norepinephrine transporter activity in adrenergic tissues, supporting the detection and staging of neuroblastoma, pheochromocytoma, paraganglioma, and assessment of cardiac sympathetic innervation.

GNH USA supplies Mibg (I123) Curium Netherlands as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, nuclear medicine departments and clinics worldwide.

What is Iodine (123i) Iobenguane used for?

Mibg (I123) Curium Netherlands is used in diagnostic imaging of conditions that involve adrenergic tissue activity.

Neuroblastoma: enables precise tumor localization and staging. Pheochromocytoma: facilitates detection of catecholamine‑producing adrenal tumors. Paraganglioma: provides imaging of extra‑adrenal sympathetic tumors. Cardiac sympathetic innervation assessment: evaluates sympathetic nerve function in heart disease.

What are the side effects of Iodine (123i) Iobenguane?

Mibg (I123) Curium Netherlands may cause a range of reactions after injection.

Common Side Effects: - Nausea or mild vomiting. - Transient flushing or warmth sensation. - Injection‑site pain or bruising. - Headache. - Mild hypotension. - Mild allergic skin reaction (rash or itching).

Serious or Rare Side Effects: - Anaphylaxis or severe allergic reaction. - Marked hypotension requiring intervention. - Radiation‑induced skin injury at the injection site. - Thyroid dysfunction due to iodine exposure. - Severe cardiac arrhythmia. - Significant radiation exposure to staff if safety protocols are breached.

What precautions apply to Iodine (123i) Iobenguane?

Prior to using Mibg (I123) Curium Netherlands, several safety considerations should be observed.

Pregnancy: avoid unless the diagnostic benefit outweighs fetal radiation risk. Breastfeeding: discontinue nursing for an appropriate period after administration. Renal impairment: assess renal function and consider dose adjustment. Thyroid blocking: administer non‑radioactive iodine to reduce thyroid uptake when indicated. Radiation safety: follow ALARA principles and protect staff and family members. Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

What does Iodine (123i) Iobenguane interact with?

Mibg (I123) Curium Netherlands can interact with other agents that affect catecholamine pathways or radiation exposure.

Major Interactions (Avoid): - Thyroid hormone therapy: may compete with iodine uptake. - Concurrent radiopharmaceuticals: increase cumulative radiation dose. - Sympathomimetic drugs: alter tracer distribution and imaging accuracy.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may reduce NET activity and tracer uptake. - MAO inhibitors: can modify catecholamine metabolism affecting image quality. - Certain chemotherapeutic agents: may interfere with norepinephrine transporter expression.

Frequently asked questions

What is Mibg (I123) Curium Netherlands used for?+
Mibg (I123) Curium Netherlands is a diagnostic radiopharmaceutical used to image adrenergic tissues. It helps locate and stage neuroblastoma, detect pheochromocytoma and paraganglioma, and assess cardiac sympathetic innervation by visualizing norepinephrine transporter activity with gamma‑camera imaging.
How does Iobenguane I-123 work in the body?+
Iobenguane I-123 mimics norepinephrine and is actively taken up by the norepinephrine transporter on sympathetic nerve endings. Once inside the cells, its radioactive iodine‑123 emits gamma photons that are captured by a gamma camera, producing detailed images of sympathetic nervous system distribution.
What is the usual dose of Mibg (I123) Curium Netherlands?+
The prescribed activity for Mibg (I123) Curium Netherlands is determined by the ordering physician based on the patient’s age, weight, and the specific diagnostic indication. The exact administered dose is individualized and should follow the prescriber’s instructions and local regulatory guidelines.
Is Mibg (I123) Curium Netherlands safe during pregnancy or breastfeeding?+
Mibg (I123) Curium Netherlands involves ionising radiation and is generally avoided in pregnancy unless the diagnostic benefit clearly outweighs fetal risk. Breastfeeding should be paused for a period recommended by the treating physician to prevent radiation exposure to the infant.
How do I order Mibg (I123) Curium Netherlands from GNH USA?+
To order, submit an enquiry on the product page at gnh-usa.com, specifying the required quantity. GNH USA works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and required import documentation.
How does Mibg (I123) compare with other diagnostic agents for neuroendocrine tumors?+
Mibg (I123) specifically targets the norepinephrine transporter, offering high specificity for adrenergic tissue. Compared with fluorodeoxyglucose (FDG) PET, it provides superior detection of catecholamine‑producing tumors such as neuroblastoma and pheochromocytoma, though it does not assess metabolic activity like FDG.
What are the storage and handling requirements for Mibg (I123) Curium Netherlands?+
The product must be stored refrigerated at 2‑8 °C, protected from light, and never frozen or shaken. It should be kept in its original container until use and handled in a shielded environment by trained personnel to minimize radiation exposure.
How is Mibg (I123) administered to patients?+
Mibg (I123) is administered as a single intravenous injection by a qualified nuclear medicine professional. After injection, a waiting period of typically 15‑24 hours allows optimal tracer uptake before gamma‑camera imaging is performed.
What are the most serious risks associated with Mibg (I123) use?+
Serious risks include severe allergic reactions (anaphylaxis), marked hypotension, radiation‑induced skin injury at the injection site, and potential thyroid dysfunction from iodine exposure. Proper patient screening and adherence to radiation safety protocols help mitigate these risks.
Who should not receive Mibg (I123) Curium Netherlands?+
Patients with known severe allergy to iodine‑123 compounds, uncontrolled hypertension, significant cardiac arrhythmias, or those who are pregnant or breastfeeding without a clear clinical justification should not receive this radiopharmaceutical. Clinical judgment is essential for each individual case.
Information provided on this page is for educational use by procurement and clinical professionals. Always consult a licensed healthcare provider for medical advice and prescribing decisions. GNH USA supplies this product subject to applicable regulatory and licensing requirements.
Send a sourcing enquiry for this product →

Product details

Drug
Iodine (123i) Iobenguane
Route
Intravenous Use
Manufacturer
Curium Netherlands B.V.
Origin
EU

Related products

Adreview

Adreview

Iodine (123i) Iobenguane

Ge Healthcare
EU
Adreview

Adreview

Iodine (123i) Iobenguane

Ge Healthcare B.V.
EU
Adreview

Adreview

Iodine (123i) Iobenguane

Ge Healthcare Buchler Gmbh & Co. Kg
EU
Adreview

Adreview

Iodine (123i) Iobenguane

Ge Healthcare S.R.L.
EU